Cargando…

Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evidence to Inform Clinical Practice

SIMPLE SUMMARY: Oncology practice in gastrointestinal tumors is moving toward therapeutic algorithms comprising multiple systemic options integrated with loco-regional strategies, such as surgery. This paradigm holds true for metastatic colorectal cancer, as well as upper gastrointestinal neoplasms,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fanotto, Valentina, Salani, Francesca, Vivaldi, Caterina, Scartozzi, Mario, Ribero, Dario, Puzzoni, Marco, Montagnani, Francesco, Leone, Francesco, Vasile, Enrico, Bencivenga, Maria, De Manzoni, Giovanni, Basile, Debora, Fornaro, Lorenzo, Masi, Gianluca, Aprile, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913845/ https://www.ncbi.nlm.nih.gov/pubmed/36765854 http://dx.doi.org/10.3390/cancers15030900

Ejemplares similares

Evolving Landscape in Liver Transplantation for Hepatocellular Carcinoma: From Stage Migration to Immunotherapy Revolution
por: Cesario, Silvia, et al.
Publicado: (2023)

HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives
por: Fanotto, Valentina, et al.
Publicado: (2016)

Primary Resistance to Immunotherapy-Based Regimens in First Line Hepatocellular Carcinoma: Perspectives on Jumping the Hurdle
por: Salani, Francesca, et al.
Publicado: (2022)

Abdominal Visceral-to-Subcutaneous Fat Volume Ratio Predicts Survival and Response to First-Line Palliative Chemotherapy in Patients with Advanced Gastric Cancer
por: Aringhieri, Giacomo, et al.
Publicado: (2023)

Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer
por: Fornaro, Lorenzo, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors in Esophageal Cancers: Are We Finally Finding the Right Path in the Mist?
por: Vivaldi, Caterina, et al.
Publicado: (2020)

Comment on: ‘Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'
por: Vivaldi, Caterina, et al.
Publicado: (2016)

Role of Baseline Computed-Tomography-Evaluated Body Composition in Predicting Outcome and Toxicity from First-Line Therapy in Advanced Gastric Cancer Patients
por: Catanese, Silvia, et al.
Publicado: (2021)

Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data
por: Fornaro, Lorenzo, et al.
Publicado: (2015)

Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials
por: Casadei Gardini, Andrea, et al.
Publicado: (2019)

Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer
por: Del Re, Marzia, et al.
Publicado: (2021)

New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury
por: Cinausero, Marika, et al.
Publicado: (2017)

Factors predicting survival in patients with locally advanced pancreatic cancer undergoing pancreatectomy with arterial resection
por: Napoli, Niccolò, et al.
Publicado: (2020)

Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy
por: Fanotto, Valentina, et al.
Publicado: (2018)

Minor-but-Complex Liver Resection: An Alternative to Major Resections for Colorectal Liver Metastases Involving the Hepato-Caval Confluence
por: Urbani, Lucio, et al.
Publicado: (2015)

Molecular classifications of gastric cancers: Novel insights and possible future applications
por: Garattini, Silvio Ken, et al.
Publicado: (2017)

Survival trends over 20 years in patients with advanced cholangiocarcinoma: Results from a national retrospective analysis of 922 cases in Italy
por: Casadei-Gardini, Andrea, et al.
Publicado: (2023)

Feasibility of BRCA1/2 Testing of Formalin-Fixed and Paraffin-Embedded Pancreatic Tumor Samples: A Consecutive Clinical Series
por: Bruno, Rossella, et al.
Publicado: (2021)

Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer
por: Fornaro, Lorenzo, et al.
Publicado: (2015)

Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology
por: Aprile, Giuseppe, et al.
Publicado: (2015)

Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study
por: Vivaldi, Caterina, et al.
Publicado: (2019)

Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer
por: Del Re, Marzia, et al.
Publicado: (2017)

Circulating tumour DNA in gastrointestinal cancer in clinical practice: Just a dream or maybe not?
por: Pretta, Andrea, et al.
Publicado: (2022)

Prognostic relevance of a T-type calcium channels gene signature in solid tumours: A correlation ready for clinical validation
por: Fornaro, Lorenzo, et al.
Publicado: (2017)

Bone metastases in biliary cancers: A multicenter retrospective survey
por: Santini, D, et al.
Publicado: (2018)

Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality?
por: Dell’Aquila, Emanuela, et al.
Publicado: (2020)

How to improve metastatic pancreatic ductal adenocarcinoma patients’ selection: Between clinical trials and the real-world
por: Pretta, Andrea, et al.
Publicado: (2022)

The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer
por: Franco, Pierfrancesco, et al.
Publicado: (2018)

Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review
por: Gardini, Andrea Casadei, et al.
Publicado: (2017)

Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study
por: Nappo, Floriana, et al.
Publicado: (2023)

The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab
por: Demurtas, Laura, et al.
Publicado: (2017)

Apatinib in Advanced Gastric Cancer: A Doubtful Step Forward
por: Fornaro, Lorenzo, et al.
Publicado: (2016)

Perspectives in the Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer Patients
por: Rosati, Gerardo, et al.
Publicado: (2021)

The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib
por: Caputo, Francesco, et al.
Publicado: (2020)

The Clinical Value of Nutritional Care before and during Active Cancer Treatment
por: Aprile, Giuseppe, et al.
Publicado: (2021)

New Horizons in Metastatic Colorectal Cancer: Prognostic Role of CD44 Expression
por: Ziranu, Pina, et al.
Publicado: (2023)

Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies
por: Fanotto, Valentina, et al.
Publicado: (2023)

The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients
por: Basile, Debora, et al.
Publicado: (2019)

Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment
por: Spanu, Dario, et al.
Publicado: (2022)

Implementation of Precision Oncology in the National Healthcare System: A Statement Proposal Endorsed by Italian Scientific Societies
por: Fasola, Gianpiero, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_805t44oel6fm6r0cscnpmlbcsi